State of the art in therapeutic drug monitoring

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 4, 2010, Pages 437-446

  Fernandez, Elena Llorente ^a,b   Parés, Laura ^a,c   Ajuria, Iratxe ^a,d   Bandres, Fernando ^a,e   Castanyer, Bartomeu ^a,f   Campos, Francesc ^a,g   Farré, Carme ^a,h   Pou, Leonor ^a,i   Queraltó, Josep Maria ^a,j,k   To Figueras, Jordi ^a,l  

^a Sociedad Española de Química Clínica ^*  (Spain)

^b Hospital V Alvarez Buylla   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL DE GALDAKAO   (Spain)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^g Hospital Universitari Parc Taulí   (Spain)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^k UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^l HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

Analytical phase; Post analytical phase; Pre analytical phase; Quality management system; Therapeutic drug monitoring

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOGLYCOSIDE DERIVATIVE; AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; BETA LACTAM ANTIBIOTIC; CAFFEINE; CANRENONE; CARBAMAZEPINE; CYCLOSPORIN; DIGOXIN; ETIRACETAM; EVEROLIMUS; IMIPRAMINE; IMMUNOSUPPRESSIVE AGENT; LITHIUM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PROCAINAMIDE; PROTEINASE INHIBITOR; RAPAMYCIN; SPIRONOLACTONE; TACROLIMUS; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

AREA UNDER THE CURVE; BLOOD SAMPLING; CAPILLARY ELECTROPHORESIS; DIGOXIN BLOOD LEVEL; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INTERACTION; DRUG MONITORING; DRUG PROTEIN BINDING; FOOD DRUG INTERACTION; GAS CHROMATOGRAPHY; HERB DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LITHIUM BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVIEW; THEOPHYLLINE BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION;

CHEMISTRY TECHNIQUES, ANALYTICAL; CLINICAL LABORATORY INFORMATION SYSTEMS; DRUG MONITORING; DRUG STABILITY; HUMANS; PRESCRIPTION DRUGS; SPECIMEN HANDLING;

EID: 77949872425     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.111     Document Type: Review

References (106)

1. UNI EN ISO 9001. Quality management systems. Requirements 2000. http://www.iso.org/iso/home.htm/ (July 2009, date last accessed). 2000.
2. UNI EN ISO 9001:2008. Quality management systems. Requirements. http://www.iso.org/iso/home.htm/ (July 2009, date last accessed). 2008.
3. Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 2001;52(Suppl 1):5S-10S.
4. Mann K, Hiemke C, Schmidt LG, Bates DW. Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. Ther Drug Monit 2006;28:83-88
5. Hammett-Stabler CA, Dasgupta A. Therapeutic drug monitoring data. A concise guide, Third ed. 2007.
6. Hammett-Stabler CA, Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry. Clin Chem 1998;44:1129-1140
7. Linder MW, Keck PE Jr. Standards of laboratory practice: antidepressant drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998;44:1073-1084
8. Valdes R Jr, Jortani SA, Gheorghiade M. Standards of laboratory practice: cardiac drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998;44:1096-1109
9. Warner A, Privitera M, Bates D. Standards of laboratory practice: antiepileptic drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998;44:1085-1095
10. Langers P, Press RR, den HJ, Cremers SC, Baranski AG, Lamers CB, et al. Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration. Ther Drug Monit 2008;30:456-461
11. Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the neoral formulation. BioDrugs 2001;15:279-290
12. Van Gelder T, Le MY, Shaw LM, Oellerich M, DeNofrio D, Holt C, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006;28:145-154
13. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009;31:139-152
14. Oremus M, Zeidler J, Ensom MH, Matsuda-Abedini M, Balion C, Booker L, et al. Utility of monitoring mycophenolic acid in solid organ transplant patients. Evid Rep Technol Assess (Full Rep) 2008;164:1-131.
15. Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R, et al. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antivir Ther 2005;10:375-392
16. Baraldo M. The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol 2008;4: 175-192
17. Amitai Y, Kennedy EJ, DeSandre P, Frischer H. Distribution of amitriptyline and nortriptyline in blood: role of alpha-1- glycoprotein. Ther Drug Monit 1993;15:267-273
18. Dasgupta A, Yared MA, Wells A. Time-dependent absorption of therapeutic drugs by the gel of the Greiner Vacuette blood collection tube. Ther Drug Monit 2000;22:427-431
19. Janknegt R, Lohman JJ, Hooymans PM, Merkus FW. Do evacuated blood collection tubes interfere with therapeutic drug monitoring? Pharm Weekbl Sci 1983;5:287-290
20. Karppi J, Akerman KK, Parviainen M. Suitability of collection tubes with separator gels for collecting and storing blood samples for therapeutic drug monitoring (TDM). Clin Chem Lab Med 2000;38:313-320
21. Boeynaems JM, De LA, Dessars B, Villa-Lobos HR, Aubry JC, Cotton F, et al. Evaluation of a new generation of plastic evacuated blood-collection tubes in clinical chemistry, therapeutic drug monitoring, hormone and trace metal analysis. Clin Chem Lab Med 2004;42:67-71.
22. Bush V, Blennerhasset J, Wells A, Dasgupta A. Stability of therapeutic drugs in serum collected in vacutainer serum separator tubes containing a new gel (SST II). Ther Drug Monit 2001;23:259-262
23. Godolphin W, Trepanier J, Farrell K. Serum and plasma for total and free anticonvulsant drug analyses: effects on EMIT assays and ultrafiltration devices. Ther Drug Monit 1983;5: 319-323
24. Shaw LM, Nicholls A, Hale M, Armstrong VW, Oellerich M, Yatscoff R, et al. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem 1998;31:317-322
25. Shaw LM, Holt DW, Oellerich M, Meiser B, Van GT. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001;23: 305-315
26. Wallace SM, Chan LY. In vitro interaction of aminoglycosides with beta-lactam penicillins. Antimicrob Agents Chemother 1985;28:274-281
27. Shipkova M, Armstrong VW, Kiehl MG, Niedmann PD, Schutz E, Oellerich M, et al. Quantification of mycophenolic acid in plasma samples collected during and immediately after intravenous administration of mycophenolate mofetil. Clin Chem 2001;47:1485-1488
28. Baumann P, Ulrich S, Eckermann G, Gerlach M, Kuss HJ, Laux G, et al. The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin Neurosci 2005;7:231-247
29. Dasgupta A. Clinical utility of free drug monitoring. Clin Chem Lab Med 2002;40:986-993
30. Chan K, Beran RG. Value of therapeutic drug level monitoring and unbound (free) levels. Seizure 2008;17:572-575
31. Sproule B, Nava-Ocampo AA, Kapur B. Measuring unbound versus total valproate concentrations for therapeutic drug monitoring. Ther Drug Monit 2006;28:714-715
32. Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003;19:825-835
33. Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta 2007;377:1-13.
34. George S, Braithwaite RA, Hughes EA. Digoxin measurements following plasma ultrafiltration in two patients with digoxin toxicity treated with specific Fab fragments. Ann Clin Biochem 1994;31(Pt 4):380-382
35. Abdel-Rehim M. Recent advances in microextraction by packed sorbent for bioanalysis. J Chromatogr A 2009.
36. Burton ME, Shaw LM, Schentag JJ, Evans WE. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring, 4th ed. Baltimore, MD: Lippincott Williams & Wilkins, 2006.
37. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit 2006;28: 468-473
38. Wang S, Miller A. A rapid liquid chromatography-tandem mass spectrometry analysis of whole blood sirolimus using turbulent flow technology for online extraction. Clin Chem Lab Med 2008;46:1631-1634
39. Koal T, Sibum M, Koster E, Resch K, Kaever V. Direct and fast determination of antiretroviral drugs by automated online solid-phase extraction-liquid chromatography-tandem mass spectrometry in human plasma. Clin Chem Lab Med 2006;44: 299-305.
40. Vogeser M, Rieger C, Ostermann H, Spohrer U. A routine method for the quantification of the novel antimycotic drug posaconazole in plasma using liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 2009;47:579-584
41. Storzinger D, Swoboda S, Lichtenstern C, Muller C, Weigand MA, Hoppe-Tichy T. Development and validation of a highperformance liquid chromatography assay for posaconazole utilizing solid-phase extraction. Clin Chem Lab Med 2008;46: 1747-1751
42. Wallemacq PE. Therapeutic monitoring of immunosuppressant drugs. Where are we? Clin Chem Lab Med 2004;42: 1204-1211
43. Neels HM, Sierens AC, Naelaerts K, Scharpe SL, Hatfield GM, Lambert WE. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 2004;42: 1228-1255
44. Thormann W, Theurillat R, Wind M, Kuldvee R. Therapeutic drug monitoring of antiepileptics by capillary electrophoresis. Characterization of assays via analysis of quality control sera containing 14 analytes. J Chromatogr A 2001;924:429-437
45. Zhang G Jr AV, Bartlett MG. Bioanalytical methods for the determination of antipsychotic drugs. Biomed Chromatogr 2008;22:671-687
46. Thormann W. Progress of capillary electrophoresis in therapeutic drug monitoring and clinical and forensic toxicology. Ther Drug Monit 2002;24:222-231
47. Warner AM, Annesly T. Standards of laboratory practice: guidelines for therapeutic drug monitoring services. An NACB monograph. Washington, DC: National Academy Clinical Biochemistry, 1999.
48. Westgard JO, Ehrmeyer SS, Darcy TP. CLIA final rules for quality systems, 1st ed., 2004.
49. Bertholf RL, Johannsen LM, Bazooband A, Mansouri V. False-positive acetaminophen results in a hyperbilirubinemic patient. Clin Chem 2003;49:695-698
50. Beuhler MC, Curry SC. False positive acetaminophen levels associated with hyperbilirubinemia. Clin Toxicol (Phila) 2005; 43:167-170
51. Polson J, Wians FH Jr, Orsulak P, Fuller D, Murray NG, Koff JM, et al. False positive acetaminophen concentrations in patients with liver injury. Clin Chim Acta 2008;391:24-30.
52. Wood FL, Earl JW, Nath C, Coakley JC. Falsely low vancomycin results using the Abbott TDx. Ann Clin Biochem 2000;37(Pt 3):411-413
53. Weber TH, Kapyaho KI, Tanner P. Endogenous interference in immunoassays in clinical chemistry. A review. Scand J Clin Lab Invest Suppl 1990;201:77-82.
54. Ezan E, Emmanuel A, Valente D, Grognet JM. Effect of variability of plasma interferences on the accuracy of drug immunoassays. Ther Drug Monit 1997;19:212-218
55. Hullin DA. An IgM paraprotein causing a falsely low result in an enzymatic assay for acetaminophen. Clin Chem 1999; 45:155-157
56. Dasgupta A, Wells A, Datta P. False-positive serum tricyclic antidepressant concentrations using fluorescence polarization immunoassay due to the presence of hydroxyzine and cetirizine. Ther Drug Monit 2007;29:134-139
57. Liendo C, Ghali JK, Graves SW. A new interference in some digoxin assays: anti-murine heterophilic antibodies. Clin Pharmacol Ther 1996;60:593-598
58. Oellerich M, Armstrong VW. Prodrug metabolites: implications for therapeutic drug monitoring. Clin Chem 2001;47: 805-806
59. Datta P, Scurlock D, Dasgupta A. Analytic performance evaluation of a new turbidimetric immunoassay for phenytoin on the ADVIA 1650 analyzer: effect of phenytoin metabolite and analogue. Ther Drug Monit 2005;27:305-308
60. Holt DW. Monitoring mycophenolic acid. Ann Clin Biochem 2002;39:173-183
61. Soldin SJ, Wang E, Verjee Z, Elin RJ. Phenytoin overview - metabolite interference in some immunoassays could be clinically important: results of a College of American Pathologists study. Arch Pathol Lab Med 2003;127:1623-1625
62. Dasgupta A, Tso G, Wells A. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay. Ther Drug Monit 2008;30:744-747
63. Steimer W, Muller C, Eber B. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids. Clin Chem 2002;48:507-516
64. Zhu Y, Valdes R Jr, Jortani SA. Application of bioaffinity mass spectrometry for analysis of ligands. Ther Drug Monit 2005;27:694-699
65. Dasgupta A, Bernard DW. Herbal remedies: effects on clinical laboratory tests. Arch Pathol Lab Med 2006;130:521-528
66. Dasgupta A, Kang E, Olsen M, Actor JK, Datta P. Interference of Asian, American, and Indian (Ashwagandha) ginsengs in serum digoxin measurements by a fluorescence polarization immunoassay can be minimized by using a new enzymelinked chemiluminescent immunosorbent or turbidimetric assay. Arch Pathol Lab Med 2007;131:619-621
67. Dasgupta A. Herbal supplements and therapeutic drug monitoring: focus on digoxin immunoassays and interactions with St. John's wort. Ther Drug Monit 2008;30:212-217
68. Kappelhoff BS, Crommentuyn KM, de Maat MM, Mulder JW, Huitema AD, Beijnen JH. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet 2004;43:845-853
69. Droste JA, Aarnoutse RE, Koopmans PP, Hekster YA, Burger DM. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr 2003;32:287-291
70. Holland DT, DiFrancesco R, Stone J, Hamzeh F, Connor JD, Morse GD. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother 2004;48:824-831
71. Holland DT, DiFrancesco R, Connor JD, Morse GD. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther Drug Monit 2006;28: 367-374
72. Jones K, Johnston A, Holt DW. Proficiency-testing issues relating to sirolimus. Clin Ther 2000;22(Suppl B):B122-32.
73. Proposed uniform proficiency testing for Clinical Laboratory Improvement Amendments of 1988. Fed Regist 1990;55: 20896-21059
74. Walson PD. Therapeutic drug monitoring in special populations. Clin Chem 1998;44:415-419
75. Abernethy DR. Aging effects on drug disposition and effect. Geriatr Nephrol Urol 1999;9:15-19
76. Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950;29:496-507.
77. Greenblatt DJ, Sellers EM, Shader RI. Drug therapy: drug disposition in old age. N Engl J Med 1982;306:1081-1088
78. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005;44:33-60.
79. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44:989-1008.
80. Blouin RA, Kolpek JH, Mann HJ. Influence of obesity on drug disposition. Clin Pharm 1987;6:706-714
81. Anderson GD. Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Ther Drug Monit 2008;30:173-180
82. Sjoqvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther 2007;81:899-902.
83. Cuellar S, Blanes A, Fernández M. Interacciones de los medicamentos. Plan Nacional de Formación Continuada en Farmacología y Farmacoterapida. Módulo 1: Conceptos básicos en farmacología. Consejo General de Colegios Oficiales de Farmacéuticos de España 2002;77-124.
84. Joerger M, Huitema AD, Boogerd W, Van Der Sande JJ, Schellens JH, Beijnen JH. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic Clin Pharmacol Toxicol 2006;99:133-140
85. Otagiri M. A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab Pharmacokinet 2005;20:309-323
86. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 2007;22:328-335
87. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61:246-255
88. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996;31:47-64.
89. Kashuba AD, Park JJ, Persky AM, Brouwer KL. Drug metabolism, transport and influence of hepatic disease. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, editors. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. Baltimore, MD: Lippincott Williams & Wilkins, 2006.
90. Armijo JA, Sanchez MB, Campos C, Adin J. wThe interactions of antiepileptic drugs in oncology practicex. Rev Neurol 2006;42:681-690
91. Dasgupta A, Okhuysen PC. Pharmacokinetic and other drug interactions in patients with AIDS. Ther Drug Monit 2001; 23:591-605.
92. Izzedine H, Launay-Vacher V, Baumelou A, Deray G. Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int 2004;66:532-541
93. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-481
94. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61:246-255
95. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, et al. Herb-drug interactions: a literature review. Drugs 2005;65: 1239-1282
96. Venkataramanan R, Komoroski B, Strom S. In vitro and in vivo assessment of herb drug interactions. Life Sci 2006;78: 2105-2115
97. Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet 2006;45:449-468
98. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol 2006;62:225-233
99. Dietary influences on drug disposition. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, editors. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. Baltimore, MD: Lippincott Williams & Wilkins, 2006.
100. Lieber CS. Interaction of ethanol with other drugs. In: Plenum Medical, editor. Medical an nutritional complications of alcoholism. Mechanisms and management. 1992.
101. Bustad A, Terziivanov D, Leary R, Port R, Schumitzky A, Jelliffe R. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet 2006;45:365-383
102. Goicoechea M, Vidal A, Capparelli E, Rigby A, Kemper C, Diamond C, et al. A computer-based system to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug monitoring. Antivir Ther 2007;12:55-62.
103. Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet 2003;42:883-908.
104. Tsuchiwata S, Mihara K, Yafune A, Ogata H. Evaluation of Bayesian estimation of pharmacokinetic parameters. Ther Drug Monit 2005;27:18-24.
105. Bigos KL, Bies RR, Pollock BG. Population pharmacokinetics in geriatric psychiatry. Am J Geriatr Psychiatry 2006;14: 993-1003.
106. Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit 2005;27:10-17